A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity
Open Access
- 26 January 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (3) , 810
Abstract
Background/Objectives: The aim of this study was to examine the incidence and severity of refractive errors that occur following the treatment of retinopathy of prematurity (ROP) with anti-vascular growth factor (anti-VEGF) agents and laser photocoagulation. Methods: A review of the literature using three databases (PubMed, Embase, Medline) was performed using appropriate search terms, and the results of the relevant studies were compiled and extracted for descriptive analysis. Results: Sixty articles were identified. The cohorts in the studies were treated with either anti-VEGF monotherapy, laser photocoagulation, or a combination, with a high prevalence of myopia, ranging from 0 to 47.7%. Refractive errors of myopia, hypermetropia, astigmatism, and anisometropia were considered in infants who received ocular interventions for ROP. Conclusions: In comparison to laser photocoagulation, anti-VEGF monotherapy appears to yield lower levels of myopia and anisometropia; however, the incidence of hypermetropia and astigmatism is variable among cohort groups treated with different anti-VEGF agents.Keywords
This publication has 67 references indexed in Scilit:
- Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurityEuropean Journal of Pediatrics, 2023
- Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injectionGraefe's Archive for Clinical and Experimental Ophthalmology, 2022
- Risk factors for early-onset high myopia after treatment for retinopathy of prematurityJapanese Journal of Ophthalmology, 2022
- Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatmentInternational Ophthalmology, 2022
- Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurityGraefe's Archive for Clinical and Experimental Ophthalmology, 2021
- Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of PrematurityJAMA Ophthalmology, 2020
- Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurityCochrane Database of Systematic Reviews, 2016
- Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser TreatmentJAMA Ophthalmology, 2014
- Early Refractive Outcome After Intravitreous Bevacizumab for Retinopathy of PrematurityArchives of Ophthalmology (1950), 2012